Good morning, ladies and gentlemen, and welcome to Church & Dwight's first quarter 2024 earnings conference call. Before we begin, I have been asked to remind you that on this call, the company's management may make forward-looking statements regarding, among other things, the company's financial objectives and forecasts. These statements are subject to risks and uncertainties and other factors that are described in detail in the company's SEC filings. I'll now introduce your host for today's call, Mr. Matt Farrell, Chairman, President, and Chief Executive Officer of Church & Dwight. Please go ahead, sir. Good morning, everyone. Thanks for joining us today. I'll begin with a review of the Q1 results, and then I'll turn the call over to Rick Dierker, who's our CFO. When Rick is done, we'll open the call up for questions. Q1 was another solid quarter for Church & Dwight. Reported sales growth was 5.1%, beating our outlook of 4%, thanks to stronger results across the board from domestic, international, and specialty products. Organic sales grew 5.2%, which exceeded our 4% Q1 outlook, with volume accounting for a very healthy 70% of our growth. Gross margin expanded 220 basis points. At the same time, we increased marketing spending in the quarter and gained market share in a majority of our categories. Adjusted EPS was $0.96, which was $0.11 higher than our $0.85 outlook. The results were driven by higher than expected sales growth, gross margin expansion, and a lower tax rate. We continue to grow in the online class of trade, with online sales as a percentage of global sales now reaching 20.5%. In March, we signed a definitive agreement to acquire Graphico, our Japanese distributor, for approximately $35 million. We expect the acquisition to close later this year. Graphico's annual sales are approximately $38 million. The business is based in Tokyo and has 59 employees. Since 2008, Graphico has partnered with Church & Dwight and driven OxiClean to be the number one powder pre-wash additive in Japan. The acquisition is expected to contribute to greater expansion of our business in Japan and the greater APAC region. We intend to leverage the capabilities of the Graphico team to bring additional Church & Dwight brands to Japanese consumers. Now, I'm gonna turn my comments to each of the three businesses. First up is the U.S. The U.S. consumer business had 4.3% organic sales growth. 3.3% of that was volume-driven, making this the third consecutive quarter of U.S. volume growth. Five of our seven power brands gained market share in the quarter, and private label market share in our categories remained relatively stable. Now, let's look at a few important categories in the U.S., starting with laundry. ARM & HAMMER liquid laundry detergent consumption was flat, while the category grew 2%. Many of you may recall we had pulled back on promotional activity in Q4, and that continued into early Q1. As our promotional activity normalized, ARM & HAMMER liquid laundry saw share gains late in the quarter, and the brand has continued to perform well in April. Now, elsewhere in laundry, ARM & HAMMER Unit Dose and ARM & HAMMER Scent Boosters both grew faster than their categories and grew share in the quarter. Our XTRA liquid laundry brand, which is our extreme value offering, grew consumption 6.3% and increased market share to 3.8%. Now, regarding new products, we have launched two new products into the detergent category: ARM & HAMMER Deep Clean and ARM & HAMMER Power Sheets. The first, ARM & HAMMER Deep Clean, is our most premium ARM & HAMMER laundry detergent, entering the mid-tier of liquid laundry and delivering a superior clean at a price consumers can afford. The second new product is ARM & HAMMER Power Sheets laundry detergent, which was launched online in August of 2023. ARM & HAMMER was the first major brand to offer this new unit dose form in the US. Now, due to its online success, Power Sheets is now available in select brick-and-mortar retailers. Power Sheets continues to grow online. It now has 9,000 reviews with a 4.5 rating, and both Deep Clean and Power Sheets are off to a great start in 2024, and we're excited about the early results we are seeing. Now, over in litter. ARM & HAMMER litter grew consumption 5% in Q1, which was in line with category growth. Our new lightweight ARM & HAMMER Hardball clumping litter is now expanding nationally after a successful in-market test in 2023. We expect this new litter to help ARM & HAMMER capture a greater share of the lightweight litter category. To give you a couple of facts here, lightweight litter today accounts for 16% of the clumping litter category. Our share of lightweight clumping litter has grown from 4%-6% since year-end 2023, but that compares to our 29% share in regular weight litter, so still a long way to go. Turning to personal care, Batiste continues to see strong consumption growth, with consumption up 19% in Q1, growing share to 47.5%. Batiste continues to be the global leader in dry shampoo. We are meeting consumers' desire for long-lasting results with the launch of Batiste Sweat Activated and Batiste Touch Activated dry shampoos, and so far, consumers are posting excellent reviews for both of these new innovations. Now, mouthwash. TheraBreath Mouthwash and Hero continued to perform extremely well. TheraBreath is the number one alcohol-free mouthwash brand and is now the number three brand in total mouthwash with a 16% share. TheraBreath recently entered the antiseptic segment of the category with the launch of TheraBreath Deep Clean Oral Rinse, which represents 30% of the category. Hero continues to drive the majority of growth in the acne category and has grown to become the number one brand in the larger acne category, with 19% share. Hero continues to launch innovative solutions and patches, combined with adjacent consumer needs, such as the recently launched Dissolve Away Daily Cleansing Balm. Now, there are two businesses, gummy vitamins and Waterpik, that created a drag on total company organic growth in Q1. First, Waterpik. The good news for Waterpik is consumption for our water flosser business is healthy. However, flosser shipments were affected by retailer inventory adjustments in the first quarter. This, combined with lower shower head consumption, accounted for a 1% negative drag on organic revenue growth. But we expect this to be transient. The second is gummies, which also created a 1% drag. The gummy vitamin category declined 5% in Q1, which was actually worse than our expectations for the category, and our consumption was down even greater, down 12%. We continue to move forward with our plans to stabilize our vitamin business through changes to packaging, messaging, and greater marketing investments that we've talked about with you in the past. I will close my comments on the U.S. by saying that overcoming the drag from these businesses still, and still posting a 5% organic sales growth for total company, just illuminates the strength of our portfolio. Turning now to international and specialty products. Our international business delivered organic growth of 8.8% in Q1. This is driven by strong growth in the subsidiaries, just a few call-outs, especially Mexico, Germany, UK, and France, and also had growth from our global markets group. And finally, specialty products. Specialty products organic sales increased 7.2%, primarily due to record sales in our Eurasia business, as SPD continues to expand globally. I wanna wrap up my remarks by reiterating that the company is performing well with all three divisions delivering strong growth. I wanna thank our global employees for their great efforts each and every day. Now, we rarely raise our full year outlook after only one quarter, but given our fast start, we raised our outlook for gross margin and EPS growth, and we have confidence in our new full-year forecast. Now I'm gonna turn it over to Rick to give you some more color around the quarter. Thank you, Matt, and good morning, everybody. We'll start with EPS. First quarter adjusted EPS was $0.96, up 12.9% from the prior year. The $0.96 was better than our $0.85 outlook, primarily driven from higher than expected sales growth, gross margin expansion, and a lower tax rate. Reported revenue was up 5.1%, and organic sales were up 5.2%. Organic sales were driven by volume of 3.7% and positive product mix and pricing of 1.5%. 70% of our organic growth was volume-driven, and as Matt mentioned earlier, this makes three consecutive quarters of U.S. volume growth. Our first quarter gross margin was 45.7%, a 220 basis points increase from a year ago, primarily due to productivity, volume, mix, and pricing, net of the impact of higher manufacturing costs. Let me walk you through the Q1 bridge. Gross margin was made up of the following: positive 130 basis points impact from price volume mix, and a positive 130 basis points from productivity. This was partially offset by 10 basis points from currency and 30 basis points from inflation. Moving to marketing. Marketing was up $29.7 million year-over-year. Marketing expense as a percentage of net sales was 10.1%, or 150 basis points higher than Q1 of last year and led to share gains. For SG&A, Q1 adjusted SG&A increased 80 basis points year-over-year. Other expense all-in was $20.9 million, a $2.2 million decrease, primarily due to lower outstanding debt and higher interest income. We now expect other expense for 2024 to be approximately $80 million. For income tax, our effective rate for the quarter was 19.9%, compared to 24.4% in 2023, a decrease of 450 basis points due to a high level of stock option exercise in Q1 of 2024. We continue to expect the full year rate to be approximately 23%. Now to cash. For the first three months of 2024, cash from operating activities increased to $263 million, a decrease of $10.1 million, with higher cash earnings offset by higher working capital. We now expect full-year cash flow from operations to be approximately $1.05 billion, up slightly from our previous $1 billion outlook. Capital expenditures for the first three months were $46.3 million, a $21 million increase from the prior year as capacity expansion projects proceed as planned. We expect 2024 CapEx of approximately $180 million as we complete the major capacity investments that were initiated in 2023, and we expect capital spending to return to historical levels of 2% of sales in 2025. And now for the full-year outlook. We continue to expect the full-year 2024 reported and organic sales growth to be approximately 4%-5%. We now expect full-year EPS in the range of 8%-9% growth. This is up from our previous 7%-9% and is inclusive of costs related to the exit of the Megalac business, as well as Graphico transaction costs. We now expect full year gross margin to expand approximately 75 basis points, up from previous range of 50-75 basis points. Given our outstanding Q1 margin expansion of 220 basis points, this outlook implies moderate gross margin expansion for the remainder of the year. We continue to expect an increase in manufacturing costs to be more than offset through productivity, mix, higher volume, and carryover product pricing. We continue to expect marketing as a percentage of net sales to be approximately 11%. ... SG&A is now expected to be flat as a percentage of net sales compared to 2023, reflecting the investments we are making in our international and e-commerce infrastructure and costs related to the Graphico acquisition Matt discussed earlier. For Q2, we have a strong outlook and expect reported sales growth of approximately 3.5%, organic sales growth of approximately 4%. We had a really strong April from a consumption perspective, so some might be expecting a higher organic growth outlook. Our 4% outlook reflects higher coupons and trade promotion in support of new products. We're fully lapping 2023 price increases, and we're lapping a year ago distribution gains for Hero. Moving on to the rest of the P&L, we expect moderate gross margin expansion in the quarter in Q2, as we have less of an impact from carryover pricing, increased marketing spending to support our innovation pipeline, higher SG&A expense, and a significantly higher tax rate of 24% compared to the prior year of 17.9%, which benefited from a high level of stock option exercises. This represents a roughly $0.07 drag on EPS. As a result, we expect adjusted EPS of $0.83 per share, down 10% versus last year, adjusted Q2 EPS. And with that, Matt and I would be happy to take any questions. Thank you. At this time, if you'd like to ask a question, please press the star and one on your telephone keypad. You may remove yourself from the queue at any time by pressing star two. Once again, that is star and one to ask a question. We'll take our first question today from Chris Carey with Wells Fargo Securities. Hi, good morning, everyone. Hey, Chris. Just regarding the, you know, the Q4 outlook for organic sales to be below the, you know, the run rate that we're seeing in the scanner trends, Rick, you mentioned a trade promotion lapping of Hero, or excuse me, I think TheraBreath or Hero distribution gains, if you could confirm that. How would you contextualize the drivers of those two items, you know, for the organic sales outlook in Q2 being below what we can see in the consumption trends? And then I have a follow-up. Yeah. Thanks for the question, Chris. You're right. You know, April was around 6.5% consumption growth. Really, really strong, and we said three things really driving a lower organic outlook of around 4%, which is probably in the grand scheme, Hero lapping the year-ago distribution gains, we went national for Hero, was probably the biggest one, and then number two, not getting any contribution from pricing. We've fully lapped 2023 pricing actions by, you know, as we enter into Q2, and then the third one would be higher coupons and trade for supporting our new products, because this is one of our best years of innovation. Okay. That's helpful. The second thing would just be, you know, we're seeing an improvement sequentially in laundry volumes. Obviously, there's been some noise in this category with compaction, with stepped up promotional activity in the year ago base. How would you, you know, characterize your expectation for laundry sequentially from here? Clearly, we're seeing the improvement as those laps normalize. Would you expect to continue to see that improvement going forward? And do you just have any expectation for how volumes might shape up in laundry, specifically over the next couple of quarters? And if I could sneak in, are you starting to see any, you know, competitive activity in your litter business, which is what we're hearing from one of your competitors. Thanks. Yeah, you got a lot of questions there, Chris. I promise that's everything. Yeah, so if you look at laundry category, you got-- there's a lot going on there. You got liquid laundry, you got unit dose, and you got scent boosters. So if you look at, well, the categories the last three quarters for each of those, like, liquid laundry sort of decelerated year-over-year growth, Q3, Q4, Q1. It's like up 5%, up 2%, up 2%. And so it has decelerated. What-- the reason we feel good about where we stand right now is we know we lost some share in the early in the quarter, then we normalized the trade spend, and then we're gonna have even more couponing and trade, you know, going forward. Why? Because of we got Deep Clean that we've launched nationally. So, we think that, you know, we make that stick in, you know, in mid- and high mid-tier, and that could provide years of growth for us. So I think the horse to ride this year in laundry is gonna be Deep Clean. As far as unit dose and scent boosters go, you know, unit dose, that's decelerated as well, you know, last three quarters, 8, 5, 3. But we, you know, our unit dose grew 34% in the quarter, so we had a lot of success, a lot of trade done going on there. And then scent boosters, which is a very discretionary category, you know, last three quarters is 2, 1, 1, as far as the year-over-year growth, and we grew 7% because we're a value in that category, so we're in a good position, both in unit dose and in scent boosters. So then when you talk about the how promotional things are right now, like liquid laundry, if you went to Q4 versus Q1, it's up a bit, it's like up 70 basis points. So it's, and this is in measured channels, of course. And of course, you can't see coupons as well if you have good IRR in Nielsen, but if you look at the sold-on deal, it went from 33.2 to 33.9, just sequentially. So you wouldn't say, well, that's not that big a move, but year-over-year, Q1 to Q1, it's up 180 basis points. So, we would still say that, if you go down back to, pre-COVID times, if you went back to, say, 2018, it's about a 40% sold on deal. So we're a long way from being where we used to be. But I'd say trend-wise, if you drew a trend line, you'd say it is inching up, over the last, you know, six to eight quarters. The, you mentioned litter as well. You know, litter is the same sold on deal in Q1 as Q4, it's 15.3%, but still up year-over-year, 40 basis points, but, you know, a long way from where it was. If you went back years ago, it'd be more around 20%. So, but it is... Obviously, we had one competitor that was out of stock for a while, so they'll need to, I suspect, be promoting to win back share. But, like I said, we've—the horse we're riding there is Hardball. You know, we have—we got a lot of opportunity in the lightweight litter category. So that's, you had a long question, so it's kind of a long answer, but did I hit most of the points, Chris? That's perfect. I will cede the floor. Thank you very much. Okay, Senator. Thank you. Our next question will come from Rupesh Parikh with Oppenheimer. Good morning, and thanks for taking my question. Also, congrats on a nice quarter. So just going back to the vitamin category, just curious, what continues to weigh on the category? And then how should we think about expectations for the balance of the year versus, I guess, the double-digit consumption decline we just saw in Q1? Yeah, well, you know, if you look at the category, you know, the Q4 and Q1, just round numbers, are both down 5%. You know, down 5, down 5. And normally, you would expect, you know, the New Year's resolutions and people wanting to get healthy, that would be a boost to the category. You didn't see it in Q1. So, it was two things. It still is probably the tail from, you know, post-COVID, but also, you know, it's, you could also argue that for many people, it's the discretionary. So, the third thing, though, is that people moving from gummies to other forms, and that is powders and also things like chewables. We're launching a chewable this year, so we could see some of that shift to other forms. But I would say those are the dynamics that we're looking at. Now, as far as you know, our performance, yeah, we've had double-digit decline in Q4 and Q1, so obviously not happy about that. Takes a while to turn that around. You probably are starting to see new packaging in store, not only new packaging, but higher marketing spend as well. We are seeing signs of retailer support with respect to you know, shelf placement and facings, you know, pre- and post-reset. So, we you know, hope that this is the year we're gonna stabilize. We're, you know, we're really hoping that in the second half of this year, that this business will inflect and start to grow. But, we've been down, you know, Q4 and Q1, as I said. Great. And then maybe just one quick follow-up for Rick. So you guys raised the bottom line guidance, but still kept the same top-line guide, even, you know, with the Q1B, and sounds like strong demand in April. So just curious, in terms of, is it just conservatism for reaffirming the guide, or is it still just early in the year? Yeah, I think Matt's comment was spot on in his prepared remarks. Usually after Q1, we don't touch the outlook. Gross margin was so strong in Q1, we felt like we had to reflect that, and as a result, earnings was very strong as well. So that's why we adjusted it. You know, 4-5 isn't a great guide. You know, we said 4.5 pretty much throughout the year. So, you know, I would expect us to talk more about the outlook in July. Great. Thank you. I'll pass along. Our next question will come from Dara Mohsenian with Morgan Stanley. Hey, good morning. Dara, how are you? So, first, just a clarification on Waterpik. The 100 basis point issue you mentioned in Q1, is that something that fully comes back in the balance of the year? Is that embedded in the Q2 guidance? Is it more spread out in the balance of the year? And was that just a shipment issue, or is there some form of retail sales weakness also? And then maybe just broader, Matt, on, on the U.S. business. You're obviously excited about innovation this year. You mentioned the couponing in Q2. Can you talk about the level of contribution you're expecting from innovation this year, and maybe on some of the key early ones, the reception you're seeing so far from a trade and consumer standpoint? Yeah, okay. Another multi-parter. Let's just take Waterpik first. I'll say, make a few comments about that, and Rick can build on that, and we'll come back to what we're expecting for the U.S. As far as Waterpik goes, yeah, it was, you know, it was down in the first quarter, but we still expect on a full year basis, this business to be up and, you know, to hit its plan. So, I wouldn't be completely alarmed about the Waterpik activity in Q1. You know, the fact that the flosser consumption is healthy is a real positive for us. Now, that's a really strong way to start the year. Yeah, I mean, consumption for Waterpik is high, up high single digit, low double digit, so consumption's great. We had to work through some inventory that was higher than, I guess, at retail, and that's been worked through now, so we feel like it's in a good spot, as we move forward. Yeah, and as far as you know, our expectations for the year, I mean, you know, we called a 4%-5% organic growth for the year. And you know, we expect just ballpark, about 2% of that as being driven from new product launches, which is a big number. And but if you kind of roll through, we've got Deep Clean launching in laundry. And ARM & HAMMER, we're going national with ARM & HAMMER Litter, we're going national with Hardball. So those are our two big businesses on the household side of the house. And then when you get into the personal care, TheraBreath is launching with it representing 30% of the category. That's gigantic. So we're only just getting started there. And the Batiste, I mentioned, we're the number one dry shampoo in the world. You got this Batiste Touch, Batiste Sweat. They're getting really high ratings and early days, the velocities for virtually everything that we've launched are meeting or exceeding expectations. So I would suggest we feel good about, at least after one quarter, that we're gonna hit that 2% number for organic sales growth in 2024. And that'll probably be one of our biggest years ever as far as the contribution of our organic sales from new products. Great. Thanks. Okay. Our next question will come from Andrea Teixeira with JP Morgan. Thank you. Good morning. So I was hoping you can talk about, like, the dynamics as you set up your shelves. If there is anything you would call out in terms of the any pull forward in shipments and consumption. I understand that obviously, you had a very strong quarter, but you're guiding more conservatively into the second quarter. Just trying to understand the puts and takes or anything that you see the lapse. And I appreciate when you gave us the lapse on some of the components last year. But also, if you're seeing your competitors being more, I would say, more aggressive in litter or things like that, that some of them had suffered from, obviously, the cyberattack and all of that, how are the dynamics in terms of market share, as we think into the second quarter and the balance of the year? Thank you. Yeah. Well, hey, Andrea, it's Rick. I'll give you a couple of comments, and if Matt wants to add. So first of all, for the Q2 call, I went through a little bit of the details, but really, it's you know, new product, couponing and trade promotion is kind of a little bit of a step down or step up in Q2, so that's impacting net sales. We had a year ago, Hero gained as we went national. That's what I said before. And then we're lapping some of the price increases, right? Almost all of our volume, all of our organic growth from here forward is almost 100% volume driven, okay? So we had 70% in Q1, but as we move forward, it's closer to 100%. As for litter, Matt went through the amount sold on deal. You know, it has ticked up a little bit. Private label is up a little bit more, spending is up a little bit, but by and large, our shares are strong in litter. Yeah, and as far as you mentioned, the supply difficulties of other competitors. Yeah, sure. Obviously, we and other brands in the category can benefit and have benefited from that difficulty. And when you have repeat purchases over and over again, oftentimes, those changes stick. So, naturally, that's our expectation that, yeah, we're gonna hang on to some of those new consumers that moved our way, but some will be tempted back by promotions. That's super helpful. Thank you. Our next question will come from Nik Modi with RBC Capital Markets. Yeah, good morning, everyone. Just, two quick questions. Rick, maybe on just the marketing guidance. I guess based on our math, the rest of the year would imply, you know, kind of, you know, reduced marketing, of course, off of very big increases from the year ago. But just wanted to get kind of philosophically, if you kind of saw the upside, would you have a bias to reinvest more given the consumer environment, or would it be more flowing through to the bottom line? And then the second question is really around reinflation, right? We're starting to see some commodities across the energy complex reinflate, and I would just be curious on kinda how you think about managing that against this consumer backdrop in terms of pricing. Thanks. Yep. Thanks for the question, Nik. For marketing, we were up 150 basis points in Q1. We expect to be up in Q2, and then Q3 and Q4, but Q3 up probably, and then Q4 down. And why is that? We spent a lot of marketing in Q4 a year ago. We wanted to move and shift part of that to the front half as we supported our new products. So we did that in a meaningful way. Feel really good about that. On an absolute basis, marketing in Q4 would still be a high number. So we feel like we're supporting the brands great. To the extent that we overdeliver and have the momentum, we've typically looked to reinvest in marketing because it drives share, it drives organic growth, and it's a virtuous cycle. On inflation, I would say for us, it's largely unchanged. You know, inflation expectations aren't moving much at all. Ethylene is down a little bit, HDPE is up a little bit, but net-net, we're right where we were when we talked three months ago. So we don't have. You know, if there's a theoretical question of if there's inflation, what do we do? I would tell you our productivity program is very strong right now, and we think that's gonna be evergreen as well. ... Yeah, and just to add to that, Nik, as you know, we got a portfolio of value brands. So, you know, to the extent that interest rates stay where they are, obviously, we have some defense against that. We have found that, you know, Hero and TheraBreath are really high rings, but we've really been unaffected by any decline in consumer sentiment, you know, over the past few quarters. So, they seem to be somewhat resilient, and those are some of our bigger growers right now. So we still think we're pretty well positioned, at least for the remainder of 2024. Great. Thanks, guys. I'll pass it on. Okay. Our next question will come from Peter Grom with UBS. Thanks, operator. Good morning, everyone, and hope you're doing well. I was hoping to just follow up on the 2Q organic sales outlook. Rick, you mentioned fully lapping pricing. You touched on the couponing many times throughout this call. So within that 4%, can you maybe unpack what we should expect from a price versus volume perspective? And then kind of the same question for the full year. I think previously the expectation was that volumes would be kind of 2/3 of the full year organic sales growth. Has that changed, or is that still the right expectation? Thanks. Yeah. Thanks, Peter. You know, in Q1, it was 70% volume and 30% price. And I just made the comment that on a go-forward basis, Q2, Q3, Q4, they'll likely be closer to 100% volume and minimal price, if anything. And if you rewind the clock, you know, pre-COVID, you go back 10 years ago, and that was our track record, you know, 100% volume-driven growth. And actually, in the past, it was maybe 110% volume-driven growth and a little bit more trade as we went national for some of our brands. But so that's the expectation as we look forward. And so for the full year, I probably wouldn't change the outlook we gave you on the mix. Great. And then maybe just a quick follow-up on Dara's question. You know, just kind of on Waterpik and, and the fact that you expect it to, to kind of reverse and grow for the year, a pretty nice rebound. So just maybe thinking about the sales kind of from a brand perspective, just in that you, you know, over-delivered versus the full year outlook despite that drag. What really gets worse from here? Is it simply just cycling the tough comps and moderating growth in Hero and TheraBreath, or are there other brands where you're kind of expecting things to slow sequentially? No, look, we think not much changed from our original outlook. You know, we beat the quarter on our organic sales growth, and despite some of these things that were dragging us down, it's just early in the year to call any incremental upside, and we typically don't do that. So let's see how consumption goes, and, you know, we continue to do well on a share perspective, and I think we're, you know, very optimistic about the year and the top line. Thanks so much. I'll pass it on. Our next question will come from Anna Lizzul with Bank of America. Hi, good morning. Thank you for the question. With the solid volume growth that you saw in Q1, I was wondering if you're seeing a more significant benefit from trade down. I think you mentioned some in laundry in response to Chris's question, but wondering if you're seeing this elsewhere as well. And then we've been hearing from some companies this earnings season that the lower-income consumer appears to be more challenged. I was wondering how you're thinking about sort of the broad health of the consumer across your different income tiers, in relation to your categories and volume growth. Well, with respect to the consumer, you've probably heard us say on other calls that our big barometer is always unemployment, and unemployment has been consistently low. Yeah, you know, interest rates have risen, but they've been high now for a while, so we don't see any change other than maybe people are disappointed that they're not coming down as fast. So, yeah, and there's we all know that student loans started to restart as well, so there's other pressures on the consumer. We know the credit card debt is rising, delinquencies are rising. We're all looking at the same data, but it doesn't seem to be translating down into consumption for our products since you've seen the first four months of the year. I think that's probably because of, it's gotta, you gotta go category by category and brand by brand. So, like I said earlier, I do think we're well positioned for the remainder of the year. Yeah, what was the first part of your question? Just wondering if you're seeing broad trade down? You mentioned some in laundry. Any other categories? Yeah, well, well, look, the predominant portion of our portfolio that is value is laundry and litter. And, you know, in laundry, we have, obviously, we have ARM & HAMMER, but we also have XTRA. And XTRA grew in the first quarter, as it was in my prepared remarks, so you'll feel real, real good about that. And that may be an indication of more pressure on the consumer when you see the deep value brand growing. And, and, oh, and then over in litter, yeah, we have both a high-price litter, meaning premium litter, we call it the black box, and we have the orange box, which is value. So we keep people in the category. So people may trade down, but they'll trade down within ARM & HAMMER, which actually supports our top line. So like I said before, that we have some good dynamics in those two big categories that we think are gonna help us for the remainder of the year. Great. Thanks very much. Our next question will come from Bonnie Herzog with Goldman Sachs. All right, thank you. Good morning. I, I had a quick follow-up on laundry. Curious to hear how you guys think about managing the balance between driving share and profitability? ... you know, I guess I'm thinking about as you step up trade spend, you know, and also as you, you know, especially as you look at it in the context of curtailing some of the ineffective promos you mentioned earlier. Hey, Bonnie, it's Rick. I just wanna be really, really clear. You know, in Q4 of last year, we didn't repeat some bad promotions, and that carried over a little bit into January, and then we were pretty palms up about that. We have a great balance between what we think the right trade spend is and the right growth, and we're just getting back to what we would say was normal before we kinda culled some of those bad promotions. So it's not like we're hiking up trade spend to be above category levels or anything like that. We are just, you know, bumping it back from an artificial low. Yeah, our practice generally is we're generally below the category average in liquid laundry from a sold on deal perspective. Okay, that's helpful. And then I just had another question on international business. You know, your sales growth in the quarter was quite strong at nearly 9%, and the growth really seems pretty broad-based and balanced. So just curious to hear, you know, how much of the volume growth was driven by distribution expansion versus, you know, just maybe strength in your existing markets? Thanks. Yeah, I think one of the things to point to in international, and you're right, that all six subsidiaries grew as well as the GMG, so clearly ran the table. But what we're seeing the benefit of is that we're being very selective about what brands we're gonna support and what retailers we wanna grow with, and we're leveraging revenue growth management far more than we had historically, and that's true in the last 18 months, and it's really showing up in the first quarter. You know, in the past, you may have heard us talk about Global Markets Group. It's grown, you know, 15% annually for a lot of years. Well, it was a Global Markets Group that generally would be driving the international number. Well, that, that's not true in Q1. In Q1, it's the subsidiaries that are driving it, and it's for those three reasons that I gave, being selective with respect to brand, with respect to retailer, and using all the tools of revenue growth management. Yeah, the second thing that's helping international is a couple of these new brands, well, Hero and TheraBreath. And, you know, typically it takes us two to three years to get new brands, new acquisitions out internationally, and we're doing it rapidly, and there's been a great response to many countries and many distributors for those brands. Yeah, we think that'll build throughout the rest of the year. But, that, that's a nice tailwind on top of what I said, my other remarks. Okay, thank you. Our next question will come from Olivia Tong with Raymond James. Great, thanks. Good morning. Wanted to ask you about the Graphico acquisition and, you know, what drew you to that? Are there other markets that have distributor relationships, and does that seem like an area where you may be interested in more deals? And then just on, you know, thoughts on the M&A environment overall, particularly in goods, what you're seeing, and interest there. Thank you. Yeah, well, it's, if you go back a few years, the way we got established in Germany was, we had a very small distributor that had introduced Batiste into Germany, and that wound up being the basis for starting a very small subsidiary in Germany, which has grown over time. This one is different in that, Graphico is a public company in Japan, obviously a micro cap, but they have been working with OxiClean for 25 years, even before the Church & Dwight bought the business back in 2008. And you know, they have a very capable team that's driven the brand to be number one pre-wash additive and powder in Japan. So we benefit then from getting just buying a critical mass of talent in Japan, that now we can introduce our other products into Japan. The thing to keep in mind is when you oftentimes have multiple distributors in a country, because you know some distributors are household, some are personal care, they're experts in different areas. This enables us to concentrate our brands through one subsidiary. Will there be other distributors in Japan? Yeah, there could be a couple others, but this is one where we can have a base of operation. We should have a... This should be a really big business for us, given the size of the economy and the population in Japan. But also, it's a really nice beachhead for us in Southeast Asia from which to grow, so we're really, really enthusiastic about it. We've got a great team that's coming on board as a result of this acquisition. And then just thinking through about the, you know, the M&A environment overall. Well, look, you know, we're always on the hunt. It's the highest and best use of cash for the company, or we have a disproportionate amount of our cash that goes towards acquisitions. And there's always something for sale, but that's about as far as I can go right now. Great, thanks. And then just one on, following up on Bonnie's question around promotion. You know, you talked about it continuing to creep up, but, but still obviously well below pre-COVID norms. Is, is your expectation that it does get back there or just continue to show creep through the year? And then on the couponing, just a point of clarification: Is this more than normal or more a function of the timing of new products and the trial build and couponing, couponing that goes with that to support the launch? Yeah, it's really more on your second question. It's more your second explanation. It's incremental couponing to support, you know, higher and more new products is the short story. On the on your first question on amount of promotion and really trade spend, I think it's same that we told Bonnie, it's the forward look for promotion for laundry is always dependent upon how category growth is doing. And if category growth is stable, then normally promotion stays in line. And right now, category growth is great, so. Yeah, the other thing to keep in mind, Bonnie, is, you know, all those price increases that went through the last couple of years, they were really, you know, unusual for all, you know, CPG and food companies. So, yeah, that does obviously make it more expensive for the product, but didn't necessarily expand gross margins for people. So, yeah, I don't-- Like Rick said, we have to react to what's going on in the category, so it's, you can't really predict or, we're certainly not gonna telegraph what we might be-- our plans might be for the remainder of the year. Got it. Thank you. Our next question will come from Lauren Lieberman with Barclays. Great. Thanks. Good morning. I was curious in thinking about the gross margin progression from here and for the rest of the year. One of the things you called out with regard to sales slowing down, particularly, you know, starting next quarter, was that lapping on distribution gains from Hero. So I was just, you know, what we can see in Nielsen, which I know isn't representative of the full distribution of the brand, is that, you know, like, let's call it same store sales, still really, really strong. But is some of the slowing down that's implied in Hero also impacting that gross margin forecast going forward? 'Cause I imagine, and we know it's super accretive, and so I just wanted to talk about how to think about the contribution of Hero to that gross margin build as we, you know, move from here and start to lap the distribution. Thanks. Yeah, no, no problem, Lauren. This is Rick. That isn't really in our thinking as we move forward. The two things that are driving gross margin to maybe not grow as fast would be less carryover pricing, and that's kinda what I talked about from the organic revenue side, too. So we're fully through all the carryover pricing. And then number two, we talked about it during our Analyst Day in January, we're adding more fixed costs to the system for capacity reasons, like new distribution centers. Those are coming online as we move through the year. So those are the two things. Our next question will come from Javier Escalante with Evercore ISI. Hi, good morning, everyone. I do have a follow-up on the gap between retail sales that we see and the reported domestic number. You flag Waterpik as a point of impact, but we use Circana, and I believe that you guys do, too. The retail takeaway is more about 7-8%, so that is a little bit of a still kind of like a two-point gap. Do you think that is related to slow retailer reorders, as your competitor in laundry mentioned earlier in the season? I have a follow-up. Yeah. Are you comparing, Q1 when your, for your question? Correct. Yes, correct. Exactly, correct. It's just trying to understand whether is it something of the accounting of the couponing or something weird that basically we are overstating your retail sales growth and, and, and therefore, your, your shipment growth- Yep, I got it. No, it's interesting, and I know we all have similar, you know, databases. Our-- internally, our shipment number, of course, is organic 4.3, and then IRI, our number is around 6%. So our gap is closer to 1.5%. Part of that's the couponing, part of that is the Waterpik consumption that we've talked about, working through retail inventory. And yeah, I mean, those are the two biggest pieces. When it comes to the gross margin getting better than expected, and I know that price mix was an issue, was the driver. Is it more kind of like the change in the portfolio, meaning richer sales from Hero and TheraBreath? What was the driver of the better gross margin and therefore the earnings beat? Yeah, that's a good question. I think it was really the two things. It was mix was a little bit more helpful and volume was helpful. I mean, price came in as expected, manufacturing cost came in as expected, productivity was in line. So it was really higher volumes, which helped with throughput and efficiencies and then a little bit favorable mix. Okay. Thank you very much, guys. Our next question will come from Filippo Falorni with Citi. Hey, good morning, everyone. I wanted to follow up your point of the cycling of the distribution gains for Hero and maybe extend it to TheraBreath as well. Can you comment, like, how much incremental shelf space are you getting this year compared to last year in the U.S.? ... And then I think at CAGNY, you talked about more international opportunities for those brands. So maybe can you give us some sense of the potential contribution from international? Thank you. Yeah. Okay. Yeah, when you think about TheraBreath and Hero, you know, TheraBreath, we bought that business in 2021, Hero in 2022. So, for TheraBreath, you know, with resets this year, we're getting more doors. But I would expect that the distribution gains from a number of doors perspective is gonna plateau for TheraBreath this year, and that we're gonna be getting the way to look for distribution gains in the future are gonna be more facings. And we are seeing that already from some existing retailers where we already have good distribution, but maybe not the amount of facings we deserve. And then, so I think more facings and innovation are gonna drive future growth for TheraBreath once we plateau with respect to the number of doors. For Hero, since we've owned that a little bit less, you know, a year or less than TheraBreath, there's still some distribution gains to come with some decent-sized retailers, but we expect it's the same thing to happen. But what with respect to Hero, what we'll be starting to do is start to move from just, you know, patches and acne into adjacent consumer needs such as skincare, pre- and post acne. And you mentioned international. So international is an area where we're running to launch Hero and TheraBreath. Hero, we're planning on launching in 40 countries in 2024, and, yeah, that'll happen throughout the year. And then, of course, the sales growth will start to build in future years. But I think the other thing that's probably worth pointing out is that both Hero and TheraBreath are high-ring products. And so if you're a retailer, you really like a high-ring product for with a growing brand, and consequently, you do wanna give that brand more facings and listen to the innovation. So we think the dynamics for each of those brands are gonna bode well for growth, not only in 2024, but in 2025. Thank you, guys. I'll pass it on. Yep. Okay. Our last question will come from Brett Cooper with Consumer Edge Research. Hi, good morning. I was hoping to dig more into the Hero business in the US. So distribution is up significantly, making sort of the underlying read of demand a bit difficult. So I was hoping you could click one level below and see, and talk about what you're seeing with respect to existing consumer demand, new users, trial and repeat, and, and other drivers. Thanks. Yeah. Could you, I didn't hear the first part of your question. I'm sorry. You know, it was just, it's the Hero business in the U.S., right? So- Yeah. Huge distribution gains, right? So you see significant sales growth. So just trying to understand, I guess, one level below, and what you see from consumers that have been in the business for a while, and then what you're seeing with respect to new users, trial and repeat, and any other drivers on, on the sales growth. Well, look, the volumes for this business, you know, continue to grow, so it's not a, it's not a price driven business. And the awareness and household penetration is still ahead of us for this brand. You may remember that back in, before patches hit the scene, it was really ointments and lotions and et cetera that people were using to address acne. It's patches now that are driving the category, and our ability to grow is going to be going into adjacencies. Yeah, and I would probably say, you know, in all channels, we are growing and have positive growth, even in channels that are declining, because of some maybe macro or secular trends. So that bodes well for this brand. That will conclude today's question and answer session. I will now turn the conference over to Mr. Farrell for any additional closing remarks. Well, thanks for joining us today. We had a great quarter. We'll see everybody in July. This does conclude today's conference call. Thank you for your participation. You may now disconnect.